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Abstract
Background: Oesophageal squamous cell carcinoma (OSCC) is a major health burden in Sub-Saharan Africa, and
novel chemotherapies are urgently required to combat this disease. The heat shock protein 90 (HSP90) inhibitor
17-N-allylamino-17-demethoxygeldanamycin (17-AAG) has previously been proposed as a possible candidate drug.
NADPH quinone oxidoreductase 1 (NQO1) is known to increase the potency of 17-AAG, therefore we investigated
the effects of 17-AAG in OSCC cell lines in the context of their NQO1 status.
Methods: We used MTT assays to compare the sensitivity of a panel of OSCC cell lines to 17-AAG. Western blotting,
and RT-PCR were used to investigate NQO1 protein and mRNA levels, while an RFLP approach was used to investigate
the NQO1 C609T SNP.
Results: Expression of NQO1 markedly increased sensitivity to 17-AAG in the OSCC cell lines, while normal fibroblasts,
which expressed HSP90 at much lower levels, were more resistant to 17-AAG. In isolation, neither the C609T SNP, nor
NQO1 mRNA levels was an accurate predictor of NQO1 protein levels.
Conclusions: Since NQO1 greatly enhances the anti-cancer effects of 17-AAG, this could be used as a selective marker for
patients that would benefit most from 17-AAG chemotherapy at low doses. Testing for the presence of the C609T SNP in
both alleles could be used as a screen to exclude potentially poor responders to 17-AAG treatment at low dosages.
Background
OSCC presents a major health burden in Sub-Saharan
Africa, and novel chemotherapies are urgently needed to
combat this disease. HSP90 has been shown to be overex-
pressed in a number of cancers, and presents an attractive
target for anti-cancer therapy, as it plays a central role in
contributing to the maintenance of a number of the charac-
teristic hallmarks of cancer cells, by chaperoning key pro-
teins, and maintaining active conformations of signalling
proteins, reviewed in [1]. These include important signal-
ling proteins like EGFR and IGF1-R that have been impli-
cated in sustaining the neoplastic phenotype in OSCC [2].
Different HSP90 inhibitors have been shown to have
promise as chemotherapeutics.
These include the family of benzoquinone ansamycins
(BA’s), such as geldanamycin and its derivatives 17-AAG
and 17-DMAG. It has been suggested that 17-AAG could
be useful for treatment of OSCC [2]. There are several
drawback to this class of drugs, which are reviewed in [3],
most notably the induction of hepatotoxicity. This results
from one electron reduction by members of the cyto-
chrome p450 family. This reaction results in unstable inter-
mediates, damaging the tissue, which manifests as severe
hepatotoxicity [4]. On the other hand, the benzoquinone
ansamycins can also undergo two electron reduction by
the enzyme NADPH quinone oxidoreductase 1 (NQO1),
which results in a compound with higher affinity for
HSP90, which is therefore a more potent inhibitor [5,6].
The gene encoding NQO1 has been found to contain
a single nucleotide polymorphism at position 609. The
C609T SNP causes a proline to serine mutation at position
187 [7], allowing ubiquitination of NQO1 and reducing sta-
bility of the protein [8]. Thus, the SNP is effectively a null
mutation, as patients homozygous for T at position 609 will
express NQO1 that is rapidly degraded by the proteasome.
* Correspondence: denver.hendricks@uct.ac.za
Division of Medical Biochemistry, Department of Clinical Laboratory Sciences,
Faculty of Health Sciences, University of Cape Town, Anzio Road,
Observatory, Cape Town 7925, South Africa
© 2014 Hadley and Hendricks; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Hadley and Hendricks BMC Cancer 2014, 14:334
http://www.biomedcentral.com/1471-2407/14/334
We aimed to examine the potential of 17-AAG as a
chemotherapeutic drug for OSCC, using a panel of cell
lines with different NQO1 levels. Results indicated that
NQO1 status could be an important determining factor in
tumour response to 17-AAG. We next investigated whether
the presence of NQO1 enzyme could be predicted with
either the absence of the C609T SNP, or expression
levels of NQO1 mRNA. Although neither factor alone
was sufficient, SNP analysis could allow exclusion of a
cohort of NQO1-negative patients who would be less
sensitive to 17-AAG.
Methods
Cell lines, plasmids, transfections and drugs
17-AAG was purchased from Calbiochem. The human
OSCC cell lines WHCO1 and WHCO6, derived from
South African patients, were a gift from Prof R. Veale, and
described in [9]. The Kyse cell lines were purchased from
DSMZ, Germany. All cells were grown in DMEM with
10% FCS, in the presence of penicillin and streptomycin.
The plasmids for overexpression of NQO1 (pEFIRES-
empty, and pEFIRES-NQO1) were a kind gift from Yosef
Shaul (Weizmann Institute of Science) [10]. Cells were
transfected using Transfectin (BioRad) and transfected cells
were selected using puromycin (Calbiochem). Pools
of stably transfected cells were maintained in 1.5 μg/ml
puromycin.
MTT assay
Cells were plated in 96 well plates at a density of 5000
cells per well. The following day, cells were treated with
drug at different concentrations. After 2 or more days of
incubation, 10 μl of sterile MTT solution (5 mg/ml in PBS)
was added to each well, and plates were incubated for
4 hours. Thereafter, 100 μl of solubilisation reagent (10%
SDS, 0.01M HCl) was added to each well. Plates were in-
cubated at 37°C overnight, before the absorbance was
measured at 595 nm.
Western blotting
Proteins were harvested in RIPA buffer, and sonicated
for 10s. Protein concentration was calculated using the
BCA kit (Pierce). Equal amounts of protein were separated
on a polyacrylamide gel, and transferred to a nitrocellulose
membrane (Amersham). Membranes were blocked in 5%
fat free milk powder, before incubation with the follow-
ing primary antibodies: NQO1 A180 (sc32793); GAPDH
0411 (sc47424); β tubulin H235 (sc9104); PARP 1/2 H250
(sc7150) (all from Santa Cruz Biotechnology).
SNP analysis
Genomic DNA was harvested from cell lines using
Qiazol, according to the user defined protocol provided on
the manufacturer’s website. PCR was performed using
Amplitaq Gold (Applied Biosystems), and primer sequences
from [11]. PCR products were purified using Wizard SV
Spin columns (Promega) before being digested overnight
with Hinf1 (Thermo Scientific). Digested DNA fragments
were analysed by polyacrylamide gel electrophoresis, stain-
ing with ethidium bromide.
Quantitative RT-PCR
Total RNA was harvested from cells at approximately
60- 80% confluency using the Qiazol reagent (Qiagen),
according to the manufacturer’s instructions. After agar-
ose gel electrophoresis to confirm RNA integrity, 1μg was
reverse transcribed using random hexamer primers, and
Impromtu RTase (Invitrogen). cDNA was submitted to
quantitative RT-PCR using Sybr-fast reaction mix (Kapa
Biosystems), and primers for HSP90α (F: TGAGGACAG
ACACAGGTGAAC 3′ and R: TGGTCCAGATGGGCTT
TGTT 3′) NQO1 (F: TGAAGAAGAAAGGATGGGAG
G3′ and R: AGGGGGAACTGGAATATCAC 3′) and β
actin (F: AGGAAGGAAGGCTGGAAGAG 3′ and R: AT
CGTGCGTGACATTAAGGAG3′). β actin was used as
a housekeeping gene. Relative expression was calculated
using comparative Ct values. Results of two to three inde-
pendent experiments were pooled.
Statistical analysis
GraphPad Prism software was used for statistical analysis,
as indicated in figure legends. For MTT dose response
assays, absorbance values were analysed by nonlinear re-
gression, with a sigmoidal curve (variable slope), allowing
calculation of the IC50 value. Dose response experiments
were repeated several times in each cell line, and data were
pooled to give a more accurate estimation of the IC50 and
95% confidence intervals around the value.
Results
NQO1 enhances sensitivity of OSCC cell lines to 17-AAG
We analysed the response of a panel of OSCC cell lines
to 17-AAG. Using dose response MTT assays, we estab-
lished the IC50 concentrations of 17-AAG for each cell
line. We noticed that all the cell lines in the panel were
relatively sensitive to 17-AAG, with IC50 values in the
sub-micromolar range (Figure 1). However, five of the
OSCC cell lines were significantly more sensitive, with
IC50 values below 120 nM. On further investigation, we
found that the sensitivity to 17-AAG correlated very well
with endogenous expression of NQO1, as detected by
Western blotting (Figure 1A, bottom panel). Cell lines
with detectable levels of endogenous NQO1 were mark-
edly more sensitive to 17-AAG.
In order to confirm that the levels of NQO1 were indeed
responsible for the differences in sensitivity to 17-AAG, we
generated stable cell lines overexpressing NQO1 (WHCO1
pEF-NQO1) or the empty vector (WHCO1 pEF-empty).
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Overexpression of NQO1 was confirmed by Western blot-
ting, and NQO1 levels were found to be similar to the levels
of endogenous NQO1 in the cell lines in which NQO1 was
detectable (Additional file 1: Figure S1). Analysis of the sen-
sitivity of the stable cell lines to 17-AAG revealed that over-
expression of NQO1 resulted in increased sensitivity to the
drug, reducing the IC50 value of the cells from 0.618 μM
(WHCO1 pEF-empty) to 0.0738 μM, which is in line with
the IC50 values of cell lines that express detectable NQO1
(Figure 1A). We further confirmed the increased sensitivity
of the cells by investigating PARP cleavage, a marker of
apoptosis, in response to 17-AAG. While WHCO1 cells
transfected with empty vector only exhibited PARP cleavage
after treatment with 1 μM 17-AAG for 24 hours, NQO1
transfected cells exhibited PARP cleavage at the lower con-
centration of 0.1 μM 17-AAG (Figure 1C ).
We noted that NQO1 protein levels decreased in the
presence of increasing concentrations of 17-AAG. A
Figure 1 NQO1 increases sensitivity of OSCC cell lines to 17-AAG. (A) OSCC cell lines were analysed by dose response MTT assay, and IC50
concentrations were established for each cell line, by pooling 2 to 6 independent experiments. The IC50 value is presented in the histogram, with
error bars representing the 95% confidence interval around this value. The lower panel shows a Western blot of NQO1 levels, with β tubulin as a
loading control. The Western blot is representative of at least two independent experiments. (B)WHCO1 cells were stably transfected with pEF-empty
or pEF-NQO1. Dose response curves were performed in triplicate (error bars represent SEM). Results are representative of two independent experiments.
(C) Cells were treated with different concentrations of 17-AAG for 24 hr, and protein was harvested and analysed for PARP cleavage by Western blot.
NQO1 overexpression was also confirmed by Western blot. Results are representative of two independent experiments.
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similar effect was observed with endogenous NQO1 in
Kyse 70 and Kyse 150 cells (Additional file 2: Figure S2).
However, we did not detect a significant downregulation
of NQO1 mRNA brought about by treatment with 17-
AAG (Additional file 2: Figure S2), suggesting that the
observed downregulation at the protein level is a post-
transcriptional event.
We selected cell lines with either detectable or undetect-
able levels of endogenous NQO1, and examined their pro-
liferation over several days in the presence of increasing
concentrations of 17-AAG (Figure 2). Although none of
the cell lines showed proliferation in the presence of 1 μM
17-AAG, we observed a distinct dichotomy between those
OSCC cell lines which expressed NQO1 (Kyse 70 and
Kyse 150), which did not proliferate in the presence of
0.1 μM 17-AAG, and those in which NQO1 was not de-
tectable (WHCO1 and Kyse 30), which displayed prolif-
eration levels similar to untreated cells in the presence
of 0.1 μM 17-AAG. Western blotting for PARP cleavage
as a marker of apoptosis showed that at 0.1 μM 17-AAG,
apoptosis was induced within 24 hr of treatment in Kyse
150, and 72 hr of treatment in Kyse 70 (Additional file 3:
Figure S3A). No induction of PARP cleavage was de-
tectable in WHCO1 or Kyse 30 at this concentration of
17-AAG over a similar time frame (Additional file 3:
Figure S3 B).
Interestingly, the normal fibroblasts DMB and FG0,
were relatively unaffected by the presence of 0.1 μM 17-
AAG, and proliferated at a similar rate to untreated cells
(Figure 2). This is despite their having detectable levels
of the 17-AAG metabolising enzyme NQO1, similar to
the levels observed in Kyse 70 and Kyse 150 (Figure 3A).
This highlights the selectivity of 17-AAG for cancer cells,
presumably due to the increased reliance of cancer cells on
HSP90 [12]. As expected, we observed that the expression
of HSP90 (α subunit) is significantly higher in the OSCC
cell lines tested than the normal fibroblasts (Figure 3B),
indicative of their increased reliance on HSP90 as a
chaperone. This suggests that in NQO1 expressing pa-
tients, treatment with a low dose of 17-AAG could still
selectively target cancer cells and have minimal effects
on normal cells, even though they may express NQO1.
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Figure 2 Sensitivity of OSCC cell lines and normal fibroblasts to 17-AAG. OSCC cell lines were plated in 96 well plates, and their proliferation was
measured over several days in the presence of increasing concentrations of 17-AAG using a MTT assay. Each point was performed in triplicate, and
error bars represent standard deviation. Results are representative of two independent experiments.
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NQO1 protein levels in OSCC cell lines depend on C609T
SNP and expression levels of NQO1 mRNA
Since the presence of NQO1 was an indicator of high
sensitivity to 17-AAG, we postulated that this could be a
useful marker of a patient’s suitability for treatment with
low doses of 17-AAG. We sought to investigate whether
the presence or absence of the NQO1 C609T SNP could
allow rapid identification of cell lines with high NQO1
levels, in the hope that this may ultimately be extended
to a clinical setting, for selection of patients who would
likely respond better to 17-AAG. We used an RFLP ap-
proach to genotype the panel of cell lines used (Figure 4).
We found that all of the cell lines in which NQO1 was
detectable had at least one WT allele (CC or CT). Two
cell lines homozygous for the C609T SNP (Kyse 30 and
Kyse 450) did not express detectable NQO1, which is
consistent with this SNP allowing increased turnover
of the nascent protein. Unexpectedly, we observed that
two cell lines (WHCO1 and WHCO6) with undetect-
able NQO1 levels, were homozygous for the wild-type
(C) allele. Thus in these cell lines, the absence of detect-
able NQO1 could not be accounted for by more rapid
protein degradation caused by the C609T SNP.
In an attempt to explain this unexpected result, we ex-
amined NQO1 mRNA expression in the panel of OSCC
cell lines using real time PCR. We found that WHCO1
and WHCO6 expressed lower levels of NQO1 mRNA
than the other cell lines with at least one C allele (approxi-
mately 50-100 fold lower than Kyse 70, 150, 180 and 520).
The expression of NQO1 in WHCO1 and WHCO6 was
also approximately 25 times lower than in the two cell
lines identified as homozygous for the C609T SNP. The
lower levels of NQO1 mRNA could possibly account for
the undetectable levels of endogenous NQO1 protein in
WHCO1 and WHCO6.
Figure 3 NQO1 levels and HSP90AA1 expression in OSCC cell lines and normal fibroblasts. (A) Protein lysates of OSCC cell lines and
normal fibroblasts (DMB and FG0) were analysed by Western blot for endogenous levels of NQO1. Results are representative of 2 independent
experiments. (B) Real time PCR was used to measure levels of HSP90AA1 mRNA relative to the housekeeping gene β actin, in a panel of OSCC
cell lines and normal fibroblasts. Histogram shows pooled results of 2- 3 independent experiments, analysed by one-way ANOVA, with Dunnet’s
post-test relative to WHCO1.
Figure 4 NQO1 C609T SNP and NQO1 mRNA levels contribute
to endogenous levels of NQO1 protein. Genomic DNA from a
panel of OSCC cell lines was amplified using primers spanning the
C609T SNP. PCR products were digested with HINf1α, and analysed
by polyacrylamide gel electrophoresis to establish the presence of
the SNP. (B) Total RNA was extracted from cells at approximately
80% confluency. RNA was reverse transcribed and the abundance
of NQO1 mRNA was analysed relative to β actin mRNA using real
time PCR. Histogram shows pooled results of 2- 3 independent
experiments, analysed by one-way ANOVA, with Dunnet’s post-test
relative to WHCO1.
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Discussion
Our results show a clear correlation between NQO1
levels and sensitivity to 17-AAG as expected [5]. Although
NQO1 activation is considered necessary for 17-AAG
activity [3], even OSCC cell lines without detectable
NQO1 showed considerable sensitivity to 17-AAG, with
IC50 concentrations around 1μM. Although this might
lead one to overestimate the promise of 17-AAG as a
chemotherapeutic option for OSCC, one must be mind-
ful of the limitations of this in vitro study. Firstly, we
have not measured the negative side effects attributed to
the drug. Indeed, a recent clinical trial of 17-AAG found
that the severity of the side effects outweighed the clinical
benefit to patients with solid tumours [13]. However, this
clinical trial did not investigate NQO1 levels in the en-
rolled patients, nor has any trial testing 17-AAG done so,
to the best of our knowledge. This may have important
implications as we describe below. Secondly, there are
indications in the literature that cultured cell lines may
express higher levels of NQO1 than lung and colon pa-
tient tumour tissue [14]. We have not been able to directly
compare NQO1 levels in cell lines and OSCC tumour
tissue, but in vivo expression may well not be as high as
that observed in the cultured cell lines.
The findings of this report suggest that if patients could
be stratified on the basis of NQO1 protein levels, then
OSCC patients expressing NQO1 could potentially benefit
from administration of low doses of 17-AAG, possibly
in combination with other chemotherapeutics. This is
because NQO1 positive patients would likely be respon-
sive to much lower concentrations of the drug. The low
dose of 17-AAG would limit the extent of toxic side ef-
fects experienced, as observed in clinical trials, where at
the six lowest doses administered (6- 125 mg/m2), only
one out of 20 patients experienced dose-limiting toxicity,
compared with eight out of fifteen patients on the two
highest doses (175- 225 mg/m2) [13]. Since severe hepato-
toxicity resulting from 17-AAG treatment is reported to
be due to metabolism by a different family of reductases
[4], this is unlikely to correlate with NQO1 expression,
although this would need to be confirmed in vivo. Further-
more, very low concentrations of 17-AAG would likely
have minimal effect on normal cells, even those expressing
NQO1, due to their much lower reliance on HSP90. How-
ever, there is a clear need for further in vivo testing to con-
firm that the presence or absence of NQO1 does not affect
hepatotoxicity, and that severe side-effects can be mitigated
by administration of sufficiently low doses.
An alternative possibility may be the approach proposed
by Karkoulis and co-workers [15] for the treatment of
bladder cancer. These authors propose that the negative
side effects of BA chemotherapeutics (in this case gelda-
namycin) may be mitigated by orthotopic administra-
tion of drug. In the case of OSCC, similar to bladder
cancer, the tumour site is relatively accessible; therefore
an orthotopic delivery may also be feasible. This would
allow exposure to dosages that effectively target the
tumour, without reaching systemic concentrations that
cause hepatotoxicity.
We noticed that 17-AAG treatment resulted in a dose-
dependent decrease in endogenously and exogenously
expressed NQO1. This is similar to the effect reported by
Gaspar and co-workers [16] who suggested that this down-
regulation of NQO1 by 17-AAG may play a role in acquisi-
tion of resistance to the drug. We found that there was no
down-regulation of NQO1 mRNA levels (Additional file 2:
Figure S2), suggesting a post-transcriptional mechanism of
control. It is not clear what this mechanism may entail,
since disruption of HSP90 activity affects a wide range of
cellular functions. Although there is no evidence support-
ing a direct interaction between NQO1 and HSP90, NQO1
levels are reported to depend heavily on FAD levels [17],
which may be disrupted by HSP90 inhibition.
It was interesting to note that the absence of detectable
NQO1 in two of the cell lines (WHCO1 and WHCO6)
could not be accounted for by the presence of the C609T
SNP, but rather seemed to correlate with low expression
of the NQO1 gene. Further investigation in tumour sam-
ples could shed light on whether this accurately reflects
NQO1 expression in patients, or whether it is an artefact
of a subset of cultured cell lines. The possibility therefore
exists that expression of NQO1 could be induced in these
two cell lines under particular environmental circum-
stances, such as those which may be experienced in cells
of a solid tumour, e.g. the presence of reactive oxygen spe-
cies or hypoxia. We postulate that due to the possibility of
induction of the gene in a tumour setting, it will be neces-
sary to specifically investigate NQO1 protein levels in
biopsies, in order to estimate potential sensitivity to 17-
AAG. This could be done using protein detection (Western
blot/immunohistochemistry), or using an NQO1 enzyme
activity assay. However, the SNP could be used as a rapid
test to exclude patients with a TT genotype, who would not
express NQO1 and would therefore be poor candidates for
17-AAG treatment.
The relevance of NQO1 levels in the clinical setting has
been discussed by Siegel et al. [18]. The authors make the
point that NQO1 levels and activity may not remain stable
over the course of the treatment, limiting the predictive
value of a protein assay, and supporting use of the SNP as
a better biomarker of 17-AAG responsiveness. If the SNP
were used as a biomarker for responsiveness, patients with
the homozygous null mutation, who will certainly not
express active NQO1 could easily be excluded from 17-
AAG treatment. While SNP analysis could provide a
relatively simple tool for elimination of non-expressors,
some patients with the wild-type genotype may also ex-
press low levels of the protein, and also be less sensitive
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to 17-AAG treatment. Thus we propose that 17AAG may
still hold promise as a chemotherapy, under certain condi-
tions. These include that the drug either be administered
orthotopically, or at low concentrations, using the C609T
SNP as a screen to exclude non-expressors of NQO1 who
would be poor responders.
Conclusions
Despite the known side effects of 17-AAG, the extreme
sensitivity of NQO1-expressing cell lines to 17-AAG, com-
pared to normal cells or NQO1 negative cells, suggests that
this drug could be a useful chemotherapeutic for NQO1
positive OSCC tumours, due to the much lower concentra-
tion required for anti-cancer activity. The presence of the
C609T SNP in both alleles could be used as a screen to
exclude potentially poor responders to 17-AAG treatment
at low dosages. This warrants further investigation in an
in vivo model.
Additional files
Additional file 1: Figure S1. Expression of NQO1 in stably transfected
cells is similar to that of endogenous NQO1 in cell lines in which this is
detectable. Whole cell lysates were analysed by western blotting for
NQO1, with β-tubulin as a loading control.
Additional file 2: Figure S2. 17-AAG causes a decrease in endogenous
NQO1 levels. Kyse 70 and 150 were treated for 24 h with increasing
concentrations of 17-AAG. (A) Cellular protein was harvested and NQO1
levels were determined by Western blotting. β tubulin serves as a loading
control. (B) Real time PCR was used to measure levels of NQO1 mRNA
relative to the housekeeping gene β actin. Histogram shows pooled
results of 2- 4 independent experiments, analysed by one-way ANOVA,
but found to be non-significant.
Additional file 3: Figure S3. 17-AAG causes cell death by apoptosis.
(A) Kyse 70 and Kyse 150 cells were treated with 100 nM 17-AAG for different
time periods. Total protein lysates were analysed by Western blotting for
the presence of cleaved PARP, a marker of apoptosis. β tubulin was used
as a loading control. (B) WHCO1 and Kyse 30 were treated with 100 nM
17-AAG for 96 h and whole cell lysates were analysed as described above.
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